Frontlight ResearchEarly access
CompletedNo phase
Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis
Key facts
- Who runs it
- Zhongnan Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 99 people enrolled
- Started
- 23 Mar 2022
- Ended
- 20 Mar 2024
- Type of study
- Observational
- Record updated
- 8 May 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age 18 years or older
- Expected length of stay>24 hours in intensive care unit (ICU)
- Sequential organ failure assessment (SOFA) score ≥ 2 on ICU admission with a suspicion of infection
Who cannot take part
- anuria
- ICU readmission in 28 days
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate the efficacy of IL-37 as a biomarker to predict mortality risk in adults with sepsis.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 8 May 2024